Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Ole Maaloes Veh 3 COPENHAGEN 2200 |
Tel: | N/A |
Website: | https://www.iobiotech.com |
IR: | See website |
Key People | ||
Mai-Britt Zocca President, Chief Executive Officer, Founder, Director | Amy B. Sullivan Chief Financial Officer | Brian Burkavage Chief Accounting Officer |
Muhammad Al-hajj Chief Scientific Officer | Devin Whittemore Smith General Counsel | Qasim Ahmad Chief Medical Officer | Faical Miyara Chief Business Officer |
Business Overview |
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company's product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech's lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark. |
Financial Overview |
For the three months ended 31 March 2024, IO Biotech Inc revenues was not reported. Net loss increased 14% to $19.5M. Higher net loss reflects Research and Development - Balancingval increase of 20% to $8.9M (expense), Personnel increase of 26% to $4.8M (expense), Currency exchange gain (loss), net decrease from $258K (income) to $462K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.59 to -$0.30. |